WILEY - Knowledge For Generations
cart.gif CART |  MY ACCOUNT |  CONTACT US |  HELP    

Make a note of our new URL: www.brjdermatol.org!

British Journal of Dermatology

An Official Journal of the British Association of Dermatologists

Edited by:
Dr Tanya O. Bleiker, Derby, UK


ISI Journal Citation Reports® Ranking: 2008: 4/43 Dermatology
Impact Factor: 3.489


Publishing a unique balance of basic science and clinical research

First choice in dermatology

  • One of the top dermatology journals in the world - 2008 Impact Factor - 3.489
  • High quality original research of instant importance - 2008 Immediacy Index - 0.761

Speed of Publication

  • Rapid, robust peer review - average 15 days from submission to first decision
  • Immediate 'preprint' publication upon article acceptance
  • 70 days from receipt at publisher to print publication
  • No page or colour charges
  • Fully compliant with NIH Public Access Policy

International Readership

  • Available in more than 5,000 medical and scientific libraries worldwide
  • >80,000 page views per month
  • Free e-alerts or RSS feeds for all registered users
  • OnlineOpen - articles 'open access' upon payment of a one time author fee

Join the ranks of the best authors in the world and submit your next paper to BJD

British Journal of Dermatology publishes papers on all aspects of the biology and pathology of the skin. Originally the Journal, founded in 1888, was devoted almost exclusively to the interests of the dermatologist in clinical practice. However, the rapid development, since the 1950s, of research on the physiology and experimental pathology of the skin has been reflected in the contents of the Journal, which now provides a vehicle for the publication of both experimental and clinical ethical research and serves equally the laboratory worker and the clinician.

TopNews and Announcements

NEW - 'preprint' publication service
Further to acceptance in BJD, manuscripts are now published online immediately. AcceptedArticles are in the public domain, and citable by DOI

Articles published online ahead of print
Articles which have been fully copy-edited and peer-reviewed are published online through our Early View feature before the print edition of this journal is published

NIH Public Access Mandate
BJD is fully compliant with NIH Public Access Policy. Manuscripts will be deposited to PubMed Central (PMC) on authors' behalves. Click here for more information

Online content now available back to Volume 29 (1917)
Back issues of this journal are now available online. For further information on how to access these issues please visit our Librarian Site

Free access in the developing world

Free online access to this journal is available within institutions in the developing world through the HINARI initiative with the World Health Organization (WHO)

TopHighlights

Top 10 Most Cited Articles from 2008*

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J.-H. Saurat, G. Stingl, L. Dubertret, et al.
Volume: 158 Issue: 3 Pages: 558-566 Published: MAR 2008

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
C. Leonardi, A. Menter, T. Hamilton, et al.
Volume: 158 Issue: 5 Pages: 1107-1116 Published: MAY 2008

Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis
J.L. Abraham, C. Thakral, L. Skov, et al.
Volume: 158 Issue: 2 Pages: 273-280 Published: FEB 2008

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
T. Ruzicka, C.W. Lynde, G.B.E. Jemec, et al.
Volume: 158 Issue: 4 Pages: 808-817 Published: APR 2008

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways
K.E. Nograles, L.C. Zaba, E. Guttman-Yassky, et al.
Volume: 159 Issue: 5 Pages: 1092-1102 Published: NOV 2008

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
D. Revicki, M.K. Willian, J.-H. Saurat, et al.
Volume: 158 Issue: 3 Pages: 549-557 Published: MAR 2008

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
C-H. Yang, W-C. Lin, C-K. Chuang, et al.
Volume: 158 Issue: 3 Pages: 592-596 Published: MAR 2008

An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
E.J. Giamarellos-Bourboulis, E. Pelekanou, A. Antonopoulou, et al.
Volume: 158 Issue: 3 Pages: 567-572 Published: MAR 2008

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
J. Schmitt, Z. Zhang, G. Wozel, et al.
Volume: 159 Issue: 3 Pages: 513-526 Published: SEP 2008

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials
A.K. Brimhall, L.N. King, J.C. Licciardone, et al.
Volume: 159 Issue: 2 Pages: 274-285 Published: AUG 2008

*As per 9th December 2009